natgillin/translations-raw huggingface dataset:
H 105 A composition for the treatment and prevention of a parasitic infection or infestation in an animal, comprising an effective amount of at least one anthelmintic compound of any one of claims 1 to 14 in combination with a pharmaceutically acceptable carrier. 
Sastav koji se upotrebljava za liječenje i prevenciju parazitne infekcije ili zaraze kod životinje, naznačen time, da obuhvaća učinkovitu količinu najmanje jednog antihelmintskog spoja u skladu s bilo kojim od zahtjeva 1 do 4. u kombinaciji s farmaceutski prihvatljivim nosačem.
A targeted therapeutic fusion protein comprising an amino acid sequence at least 85% identical to a human a-N-acetylglucosaminidase (Naglu) protein, a peptide tag having an amino acid sequence at least 70% identical to amino acids 8-67 of mature human IGF-II and a spacer peptide located between the Naglu amino acid sequence and the IGF-II peptide tag, wherein the spacer comprises the amino acid sequence GAPGGGSPAPAPTPAPAPTPAPAGGGPSGAP (SEQ ID NO: 51) between the amino acids of mature human IGF-II and the amino acids of human Naglu. 
Ciljani terapeutski fuzijski protein koji sadrži sekvencu aminokiseline koja je barem 85% identična ljudskom a-N-acetilglukozaminidaza proteinu (Naglu), peptidnu oznaku koja ima sekvencu aminokiseline koja je barem 70% identična aminokiselinama 8-67 od zrelog ljudskog IGF-II i razdvajajući peptid smješten između sekvence aminokiseline Naglu i peptidne oznake IGF-II, naznačen time da razmaknica sadrži sekvencu aminokiseline GGGGS (SEQ ID NO: 12) ili GGGPS (SEQ ID NO: 14).
A method of producing a targeted therapeutic fusion protein comprising a step of: culturing mammalian cells in a cell culture medium, wherein the mammalian cells carry the nucleic acid of claim 10; and the culturing is performed under conditions that permit expression of the targeted therapeutic fusion protein. 
Postupak za proizvodnju ciljanog terapeutskog fuzijskog proteina naznačen time da sadrži korak: kultiviranja stanica sisavaca u mediju stanične kulture, pri čemu stanice sisavaca nose nukleinsku kiselinu prema zahtjevu 14; i kultiviranje se provodi pod uvjetima koji omogućuju ekspresiju ciljanog terapeutskog fuzijskog proteina.
A composition for use in treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome) in a subject comprising a fusion protein comprising an amino acid sequence at least 85% identical to a human a-N-acetylglucosaminidase (Naglu) protein, a peptide tag having an amino acid sequence at least 70% identical to amino acids 8-67 of mature human IGF-II and a spacer peptide located between the Naglu amino acid sequence and the IGF-II peptide tag, wherein the spacer comprises the amino acid sequence GAPGGGSPAPAPTPAPAPTPAPAGGGPSGAP (SEQ ID NO: 51). 
Pripravak za uporabu u liječenju Mukopolisaharidoze tipa IIIB (sindroma Sanfilippo B) kod subjekta koji sadrži fuzijski protein koji obuhvaća sekvencu aminokiseline koja je barem 85% identična sa ljudskim a-N-acetilglukozaminidaza proteinom (Naglu), peptidnu oznaku koja ima sekvencu aminokiseline koja je barem 70% identična aminokiselinama 8-67 od zrelog ljudskog IGF-II i razdvajajući peptid smješten između sekvence aminokiseline Naglu i peptidne oznake IGF-II, naznačen time da razmaknica sadrži sekvencu aminokiseline GGGGS (SEQ ID NO: 12) ili GGGPS (SEQ ID NO: 14).
A pharmaceutical composition comprising a therapeutic amount of a Bone Morphogenetic Protein-4 (BMP-4) protein for use in a method of treatment of a glioblastoma multiforme (GBM) brain tumor comprising GBM tumor stem cells and/or GBM tumor progenitor cells, wherein the therapeutic amount of the BMP-4 protein decreases the number of GBM tumor stem cells and/or GBM tumor progenitor cells, inhibits tumorigenic potential of GBM tumor neural stem cells, or reduces the kinetics of expansion of GBM tumor neural stem cells. 
Farmaceutski pripravak, naznačen time što sadrži terapijsku količinu koštanog morfogenetskog proteina-4 (BMP-4), namijenjenog upotrebi u postupku liječenja multiformnog glioblastoma (GBM), moždanog tumora koji sadrži tumorske matične stanice GBM i/ili stanice preteče tumora GBM, gdje terapijska količina proteina BMP-4 smanjuje broj tumorskih matičnih stanica GBM i/ili stanica preteča tumora GBM, inhibira tumorogeni potencijal neuralnih matičnih stanica tumora GBM, ili smanjuje kinetiku širenja neuralnih matičnih stanica tumora GBM.
The pharmaceutical composition for use according to claim 1, wherein the BMP-4 protein is effective to increase BMP-4-mediated signaling in the tumor stem cell and/or tumor progenitor cell. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što protein BMP-4 djelotvorno pojačava signaliziranje posredovano s BMP-4 u tumorskoj matičnoj stanici i/ili stanici preteči tumora.
The pharmaceutical composition for use according to claim 1, wherein the pharmaceutical composition has a pro-differentiation effect on the tumor stem cells and the tumor progenitor cells that permanently reduces the stem cell pool without affecting cell viability or eliciting apoptosis. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što farmaceutski pripravak ima prodiferencijacijski učinak na tumorske matične stanice i stanice preteče tumora koji trajno smanjuje količinu matičnih stanica, bez utjecanja na vijabilnost stanica ili izazivanja apoptoze.
The pharmaceutical composition for use according to claim 1, wherein tumorigenic potential of the tumor stem cells is reduced. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se smanjuje tumorogeni potencijal tumorskih matičnih stanica.
The compound for the use of claim 9, wherein said method comprises administering to the subject a composition comprising an excipient and a therapeutically effective amount of the compound of claim 1, or a therapeutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 9, naznačen time što navedeni postupak obuhvaća davanje subjektu pripravka koji sadrži pomoćnu tvar i terapeutski učinkovitu količinu spoja prema zahtjevu 1, ili njegove terapeutski prihvatljive soli.
The antibody of claim 1 or 2 wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')2, a single-chain antibody (scFv), a dimerized V region (Diabody), a disulfide-stabilized V region (dsFv), and a peptide comprising CDR. 
Protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što je protutijelo fragment protutijela, kojeg se bira iz skupine koju čine Fab, Fab’, F(ab’)2, jednolančano protutijelo (scFv), dimerizirano V područje (dijatijelo), te disulfidno stabilizirano V područje (dsFv).
The pharmaceutical composition of claim 8, wherein a cytotoxic substance is bound to the antibody. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je citotoksična tvar vezana na protutijelo.
The pharmaceutical composition of claim 9, wherein the cytotoxic substance is a drug, a toxin, or a radioactive substance. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što je citotoksična tvar lijek, toksin ili radioaktivna tvar.
A process for preparing a particulate pharmaceutical formulation from core particles comprising an active pharmaceutical ingredient, comprising the step of: 
Postupak za pripravu čestica farmaceutske formulacije iz čestica jezgre koja sadrži aktivni farmaceutski sastojak, koji obuhvaća korak:
mixing the core particles, water soluble and/or water swellable coating material particles, and substantially water insoluble polymer particles, to produce the particulate pharmaceutical formulation comprising coated core particles; and subjecting the coated core particles to mechanical stress to deform a coating on the coated core particles into a substantially continuous or continuous film; 
miješanje čestica jezgri, čestica topivih u vodi i / ili čestice koja bubri u vodi za nanošenje u vodi, i uglavnom uvodi netopljive čestice polimera, kako bi se proizvela farmaceutska formulacija čestica koja sadrži obložene čestice jezgre; i podvrgavanjem obložene čestice jezgre na mehanički stres kako bi deformirao premaz na obloženim česticama jezgre u biti u kontinuirani ili kontinuirani film;
wherein a volume averaged median particle size of the core particles is at least three times greater than a median particle size of both the water soluble and/or water swellable coating material particles and the substantially water insoluble polymer particles; 
pri čemu srednja vrijednost srednje veličine čestica jezgre je najmanje tri puta veća čestica od srednje veličine čestica i čestica materijala koji su topljivi u vodi i / ili čestice materijala za nanošenje u vodi i u biti čestice netopive u vodi;
at least 90 % of an amount of the active pharmaceutical ingredient that would have been released from uncoated core particles of a same composition and size dissolves in 30 minutes as determined by a USP dissolution test using a media of 7.2 pH phosphate buffer solution with 0.4 g/L sodium dodecyl sulfate at 37°C in USP Apparatus II operating at 50 RPM. 
i najmanje 90% količine aktivnog farmaceutskog sastojka koji bi bio oslobođen od neobložene čestice jezgre istog sastava i veličine, otapaju se za 30 minuta, kako je utvrđeno USP testom otapanja koristeći sredstvo od 7.2 pH otopine fosfatnog pufera s 0.4 g/L natrijevog dodecil sulfata na 37° C u USP aparatu II pri 50 okretaja u minuti.
The process of claim 1, wherein the active pharmaceutical ingredient is completely released from the particulate pharmaceutical formulation in 30 minutes in the USP Dissolution Test using a media of 7.2 pH phosphate buffer solution with 0.4 g/L sodium dodecyl sulfate at 37°C in USP Apparatus II operating at 50 RPM. 
Postupak sukladno zahtjevu 1, naznačeno time, da aktivni farmaceutski sastojak potpuno oslobađa čestica farmaceutske formulacije za 30 minuta prema USP testu otapanja koristeći sredstvo 7.2 pH otopine fosfatnog pufera s 0.4 g/L natrijevog dodecil sulfata na 37°C u USP aparatu II pri 50 okretaja u minuti.
is selected from Ala and Arg; 
je odabran od Ala i Arg;
and P2 is absent or is a sequence of 1-20 amino acid units independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn; 
te je P2 odsutan ili je sekvenca od 1-20 aminokiselinskih jedinica koje su neovisno odabrane iz skupine koja se sastoji od Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr i Orn;
wherein the compound contains one and only one Ψ and wherein said Ψ is a residue of Lys, Arg, Orn or Cys in which the side chain is conjugated to a substituent having the formula -Z2Z1; 
pri čemu spoj sadrži jedan i samo jedan Ψ i pritom navedeni Ψ je ostatak od Lys, Arg, Orn ili Cys gdje je bočni lanac konjugiran na supstituent koji ima formulu -Z2Z1;
-Z1 is a fatty chain having a polar group at one end of the chain and a connection to Z2, -X-at the end of the chain distal from the polar group, wherein the polar group comprises a carboxylic acid or a carboxylic acid bioisostere, a phosphonic acid, or a sulfonic acid group; 
je masni lanac koji ima polarnu skupinu na jednom kraju lanca i poveznica na Z2, -X- na kraju lanca udaljen od polarne skupine, dok polarna skupina obuhvaća karboksilnu kiselinu ili bioizoster karboksilne kiseline, fosfonsku kiselinu, ili skupinu sulfonske kiseline;
-Z2- is a spacer of formula: wherein: 
Z2- je držač razmaka u sljedećoj formuli:
A-B-Alk-(CO)- or a sulfonyl group of formula: 
A-B-Alk-(CO)- ili sulfonilna skupina sljedeće formule:
a method of preventing weight gain or promoting weight loss; 
postupku prevencije dobivanja na težini ili promicanja gubitka težine;
a method of lowering circulating LDL levels, and/or increasing HDL/LDL ratio; 
postupku smanjivanja razina LDL u cirkulaciji, i/ili povećanja omjera HDL/LDL;
a method of prevention or treatment of obesity, morbid obesity, morbid obesity prior to surgery, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, diabetes, metabolic syndrome, hypertension, atherogenic dyslipidimia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or microvascular disease. 
postupku prevencije ili liječenja pretilosti, morbidne pretilosti, morbidne pretilosti prije operativnog zahvata, upale povezane s pretilosti, bolesti žučnog mjehura povezane s pretilosti, apneje u spavanju inducirane preko pretilosti, dijabetesa, metaboličkog sindroma, hipertenzije, aterogenske dislipidemije, ateroskleroze, arterioskleroze, koronarne srčane bolesti, bolesti perifernih arterija, moždanog udara ili mikrovaskularne bolesti.
The compound for use according to claim 21 wherein the compound is administered as part of a combination therapy together with an agent for treatment of diabetes, obesity, dyslipidemia or hypertension. 
Spoj za uporabu prema zahtjevu 21, naznačen time, da se spoj primjenjuje kao dio kombinacijske terapije zajedno s ljekovitim sredstvom za liječenje dijabetesa, pretilosti, dislipidemije ili hipertenzije.
the agent for treatment of diabetes is a biguanide (e.g. metformin), a sulfonylurea, a meglitinide or glinide, preferably nateglinide, a DPP-IV inhibitor, an SGLT2 inhibitor, a glitazone, a different GLP-1 agonist, an insulin or an insulin analogue; 
sredstvo za liječenje dijabetesa je bigvanid (primjerice metformin), sulfonilurea, meglitinid ili glinid, poželjno nateglinid, DPP-IV-inhibitor, SGLT2-inhibitor, glitazon, različiti agonist za GLP-1, inzulin ili analog inzulina;
the agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY receptor agonist or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, melanin concentrating hormone receptor 1 antagonist, phentermine, a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist, preferably a combination of phentermine and topiramate, a combination of bupropion and naltrexone, or a serotonergic agent; 
sredstvo za liječenje pretilosti je agonist peptidnog receptora 1 koji je nalik na glukagon, agonist peptidnog receptora YY ili njegov analog, antagonist kanabinoidnog receptora 1, inhibitor lipaze, agonist melanokortinskog receptora 4, antagonist receptora 1 melaninskog koncentracijskog hormona, fentermin, kombinacija inhibitora ponovnog nakupljanja norepinefrina/dopamina i antagonista receptora opioida, poželjno kombinacija fentermina i topiramata, kombinacija bupropiona i naltreksona, ili serotonergijsko sredstvo;
wherein the agent for treatment of hypertension is an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, diuretic, beta-blocker, or calcium channel blocker; or 
dok sredstvo za liječenje hipertenzije je inhibitor enzima pretvaranja angiotenzina, blokator receptora angiotenzina II, diuretik, beta blokator ili blokator kanala kalcija; ili
the agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin and/or a cholesterol absorbtion inhibitor. 
sredstvo za liječenje dislipidemije je statin, fibrat, niacin i/ili inhibitor apsorpcije kolesterola.
• is either free of phosphate buffering agents or comprises a phosphate buffer system in a concentration of at most 0.1 mM; 
• je bez fosfatnih pufera ili sadrži sustav fosfatnog pufera u koncentraciji najviše od 0.1 mM;
The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar stabiliser is sucrose. 
Vodeni farmaceutski pripravak sukladno zahtjevu 1, naznačeno time, da je stabilizator šećera saharoza.
The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar stabiliser is trehalose. 
Vodeni farmaceutski pripravak sukladno zahtjevu 1, naznačeno time, da je stabilizator šećera trehaloza.
The aqueous pharmaceutical composition as claimed in any preceding claim, wherein the composition comprises the acetate buffering agent (or acetate buffer system) at a concentration of 5 to 50 mM. 
Vodeni farmaceutski pripravak sukladno bilo kojem od prethodnih zahtjeva, naznačeno time, da pripravak sadrži sredstvo acetatnog pufera (ili sustav acetatnog pufera) u koncentraciji od 5 do 50 mM.
to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and 
do 300 mM stabilizatora šećera, pri čemu je stabilizator šećera nereducirajući disaharid odabran iz skupine koja sadrži trehalozu i saharozu; i
A liquid pharmaceutical composition as claimed in any of claims 1 to 13 for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis. 
Tekući farmaceutski pripravak sukladno bilo kojem od zahtjeva 1 do 13, naznačen time, što je namijenjen liječenju reumatoidnog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, Chronove bolesti, ulcerativnog kolitisa, umjerene do teške kronične psorijaze i/ili maligno idiopatskog artritisa.
The aqueous pharmaceutical composition as claimed in claim 1, wherein the sugar polyol is sorbitol. 
Vodeni farmaceutski pripravak sukladno zahtjevu 1, naznačeno time, da je stabilizator šećera trehaloza.
An aqueous pharmaceutical composition as claimed in any of claims 1 to 17, a drug delivery device as claimed in claim 18, or a kit of parts as claimed in claim 19, for use in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and/or juvenile idiopathic arthritis. 
Uređaj za davanje lijeka koji sadrži tekući farmaceutski pripravak sukladno bilo kojem od prethodnih zahtjeva. Tekući farmaceutski pripravak sukladno bilo kojem od zahtjeva 1 do 13, naznačen time, što je namijenjen liječenju reumatoidnog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, Chronove bolesti, ulcerativnog kolitisa, umjerene do teške kronične psorijaze i/ili maligno idiopatskog artritisa.
A combination according to claim 1 or 2 wherein the pharmaceutically acceptable salt of abacavir is the hemisulfate salt. 
Kombinacija u skladu s patentnim zahtjevom 1 ili 2, naznačena time što je farmaceutski prihvatljiva sol spoja formule (I) natrijeva sol.
The therapeutic and/or prophylactic agent according to claim 1, wherein the tumor is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, brain tumor, neuroblastoma, glioma, thyroid cancer, myelodysplastic syndrome, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, liver cancer, gallbladder cancer, skin cancer, malignant melanoma, kidney cancer, renal pelvic and ureteral cancer, bladder cancer, uterine cancer, testicular cancer, prostate cancer, and tumors metastasized from these tumors. 
Terapijsko i/ili profilaktičko sredstvo namijenjeno upotrebi u liječenju tumora u skladu s patentnim zahtjevom 1, naznačeno time što se tumor bira iz skupine koju čine akutna mijelogena leukemija, kronična mijelogena leukemija, akutna limfocitna leukemija, kronična limfocitna leukemija, Hodgkinov limfom, nehodgkinovski limfom, tumor na mozgu, neuroblastom, gliom, rak štitnjače, mijelodisplastični sindrom, rak glave i vrata, rak jednjaka, rak želuca, kolorektalni rak, rak dojke, rak jajnika, rak pluća, rak gušterače, rak jetre, rak žučnog mjehura, rak kože, zloćudni melanom, rak bubrega, rak nakapnice i mokraćovoda, rak mokraćnog mjehura, rak maternice, rak testisa, rak prostate, te tumori metastazirali iz tih tumora.
A therapeutic and/or prophylactic agent for a tumor used for a patient with a mutation in RET and for metastasis of the tumor, which comprises a compound represented by formula (I), a salt thereof or a solvate thereof as an active ingredient: wherein R1 is a C1-6 alkyl group. 
Terapijsko i/ili profilaktičko sredstvo namijenjeno upotrebi u liječenju tumora koje se upotrebljava kod pacijenta s mutacijom u RET-u i namijenjeno upotrebi u liječenju metastaze tumora, naznačeno time što sadrži spoj prikazan formulom (I), njegovu sol ili njegov solvat, kao aktivni sastojak: gdje je R1 C1-6 alkilna skupina.
The therapeutic and/or prophylactic agent according to claim 7 or 8, wherein the patient is a patient with a point mutation in RET gene and/or protein. 
Terapijsko i/ili profilaktičko sredstvo namijenjeno upotrebi u liječenju tumora u skladu s patentnim zahtjevom 7 ili 8, naznačeno time što je pacijent pacijent točkastom mutacijom u RET genu i/ili proteinu.
A method for identifying a patient sensitive to a compound represented by formula (I), a salt thereof or a solvate thereof, which comprises the steps of: 
Postupak identificiranja pacijenta osjetljivog na spoj prikazan formulom (I), njegovu sol ili njegov solvat, naznačen time što se sastoji u koracima:
So that the final composition of the container results from the mixing of PET with a concentrated additive that contains HIPS and inorganic light-shielding fillers. 
Tako da konačni sastav spremnika proizlazi iz miješanja PET s koncentriranim aditivom koji sadrži polistiren visoke otpornosti na udar (HIPS) i anorganska punila za zaštitu od svjetlosti.
The procedure according to claim 7, such that mixing of PET with the concentrated additive containing HIPS, TiO2 and Al, occurs at a point where the PET is in solid form, as granules in a semi-crystalline state with an opaque aspect, and the concentrated additive is also in solid form, as opaque granules. 
Postupak sukladno patentnom zahtjevu 7, naznačen time, da se miješanje PET s koncentriranim aditivom koji sadrži polistiren visoke otpornosti na udar (HIPS), TiO2 i Al, javlja u točki gdje je PET u krutom obliku, kao granule u polikristaličnom stanju s neprozirnom varijantom, i koncentrirani aditiv je također u krutom obliku, kao neprozirne granule.
The procedure according to claims 6 and 7 such that, at the moment immediately prior to the mixing of PET with the concentrated additive containing HIPS, TiO2 and Al, the PET presents a higher temperature than that of the concentrated additive. 
Postupak sukladno patentnim zahtjevima 6 i 7, naznačen time, što u trenutku neposredno prije miješanja PET s koncentriranim aditivom koji sadrži polistiren visoke otpornosti na udar (HIPS), TiO2 i Al, taj PET pretpostavlja višu temperaturu od temperature koncentriranog aditiva.
Use of one or more ALS inhibitor herbicide(s) for controlling unwanted vegetation in Beta vulgaris growing areas in which the Beta vulgaris plants comprise mutations in the ALS gene encoding an ALS polypeptide containing an amino acid that is different from tryptophan at position 569 and an amino acid that is different from proline at position 188. 
Uporaba jednog ili više herbicida inhibitora ALS za kontrolu neželjene vegetacije u područjima gdje se uzgajaju biljke Beta vulgaris gdje biljke Beta vulgaris sadrže mutacije u ALS genu koji kodira ALS polipeptid koji na položaju 569 sadrži aminokiselinu koja je različita od triptofana i na položaju 188aminokiselinu koja je različita od prolina.
is halogen, preferably fluorine or chlorine, 
je halogen, poželjno fluor ili klor,
and R3 together with the carbon atom to which they are attached are a carbonyl group C=O and 
i R3 zajedno s ugljikovim atomom na koji su oni vezani su karbonilna skupina C=O i
herbicides showing a mode of action that is different to the inhibition of the ALS enzyme [acetohydroxyacid synthase; EC 2.2.1.6] group D herbicides), and wherein the non-ALS inhibitor herbicide(s) is/are selected form the group consisting of: 
herbicidima koji imaju način djelovanja koji je različit od inhibicije ALS enzima [sintaza acetohidroksi kiseline; EC 2.2.1.6] skupina D herbicida), te pri čemu je/su herbicid(i) koji nije inhibitor ALS odabran iz skupine koja sadrži:
Method for controlling unwanted vegetation in Beta vulgaris plants growing areas, characterized by: 
Postupak za kontrolu neželjene vegetacije na područjima gdje rastu biljke Beta vulgaris, naznačen time da obuhvaća: